Pemetrexed: A novel antifolate agent enters clinical practice

Expert Review of Anticancer Therapy

Volumn 4, Issue 4, 2004, Pages 511-522

  Kut, Victoria ^a   Patel, Jyoti D ^a   Argiris, Athanassios ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antifolate; Mesothelioma; Non small cell lung cancer; Pemetrexed; Solid tumors

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEMCITABINE; LOMETREXOL; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOMA; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TRANSPORT; FATIGUE; FEVER; FOLIC ACID DEFICIENCY; HEAD AND NECK CANCER; HUMAN; INFECTION; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 4444351115     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.4.511     Document Type: Review

References (65)

1. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY-231514 (MTA). Adv. Enzyme Regul. 38, 135-152 (1998).
2. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636-2644 (2003).
3. Hanna NH, Shepherd FA, Fossella JR et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22, 1589-1597 (2004).
4. Taylor EC, Kuhnt D, Shih C et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-D] pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem. 35, 4450-4454 (1992).
5. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY-231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin. Oncol. 26, 68-73 (1999).
6. Chen VJ, Bewley JR, Andis SL et al. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin. Oncol. 26, 48-54 (1999).
7. Shih C, Chen VJ, Gossett LS et al. LY-231514, a pyrrolo[2,3-D] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57, 1116-1123 (1997).
8. Shih C, Thornton D. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY-231514). In: Antifolate Drugs in Cancer Therapy. Jackman AL (Ed.), Humana Press, NJ, USA, 183-201 (1999).
9. Schultz RM, Patel VF, Worzalla JF. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY-231514. Anticancer Res. 19, 437-443 (1991).
10. van Triest B, Pinedo HM, van Hensbergen Y et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin. Cancer Res. 5, 643-654 (1999).
11. Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin. Oncol. 26, 11-23 (1999).
12. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev. Anticancer Ther. 3, 145-156 (2003).
13. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation and the effect of LY-231514 (MTA) on purine biosynthesis. Semin. Oncol. 26, 42-47 (1999).
14. Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H. Review of a promising new agent - pemetrexed disodium. Cancer 97, 2056-2063 (2003).
15. Sikora E, Jackman AL, Newell DR, Calvert AH. Formation and retention and biological activity of N10-propargyl-4-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem. Pharmacol. 37, 4047-4054 (1998).
16. Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY-231514. Cancer Chemother. Pharmacol. 44, 427-432 (1999).
17. Galivan J, Ryan T, Rhee M, Yao R, Chave K. Glutamyl hydrolase: properties and pharmacologic impact. Semin. Oncol. 26, 33-37 (1999).
18. Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin. Cancer Res. 6, 3687-3695 (2000).
19. Mauritz R, Peters GJ, Priest DG et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem. Pharmacol. 63, 105-115 (2002).
20. Rinaldi DA. Burris HA, Dorr FA et al. Initial Phase I evaluation of the novel thymidylate synthase inhibitor, LY-231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol. 13, 2842-2850 (1995).
21. McDonald AC, Vasey PA, Adams L et al. A Phase I and pharmacokinetic study of LY-231514, the multitargeted antifolate. Clin. Cancer Res. 4, 605-610 (1998).
22. Rinaldi DA, Kuhn JG, Burris HA et al. A Phase I evaluation of multitargeted antifolate (MTA, LY-231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother. Pharmacol. 44, 372-380 (1999).
23. Hammond LA, Forero M, Beeram B et al. Phase I study of pemetrexed (LY-231514) with vitamin supplementation in patients with locally advanced or metastatic cancer. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 532).
24. Nakagawa K, Kudoh S, Matsui S et al. A Phase I dose-finding study of pemetrexed with folic acid (FA) and vitamin B12 in Japanese patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 632).
25. Ouellet D, Periclou AP, Johnson RD, Woodworth JR, Lalonde RL. Population pharmacokinetics of pemetrexed disodium (Alimta) in patients with cancer. Cancer Chemother. Pharmacol. 46, 227-234 (2000).
26. Takimoto C, Baker S, Sweeney CJ et al. Phase I and pharmacokinetic study of pemetrexed disodium (LY-231514, MTA, Alimta) in patients (pts) with impaired renal function. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 368).
27. Teicher BA, Alvarez E, Liu P et al. MTA (LY-231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin. Oncol. 26, 55-62 (1999).
28. Adjei AA, Erlichman C, Sloan JA et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J. Clin. Oncol. 18, 1748-1757 (2000).
29. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY-231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59, 3671-3676 (1999).
30. Thodtmann R, Depenbrock H, Blatter J, Johnson RD, van Oosterom A, Hanauske AR. Preliminary results of a Phase I study with MTA (LY-231514) in combination with cisplatin in patients with solid tumors. Semin. Oncol. 26, 89-93 (1999).
31. Hughes A, Calvert P, Azzabi A et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 20, 3533-3544 (2002).
32. Misset JL, Gamelin E, Campone M et al. Pemetrexed/oxaliplatin combination: results of a Phase I study in metastatic solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 427).
33. Millward M, Clarke S, Beale P et al. Phase I trial of pemetrexed (Alimta™) and vinorelbine in patients (pts) with advanced cancer. Proc. Am Soc. Clin. Oncol. (2001) (Abstract 2102).
34. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D. Interaction of pemetrexed disodium (Alimta, multitargeted antifolate) and irradiation in vitro. Int. J. Radiat. Oncol. Biol. Phys. 52, 1381-1388 (2002).
35. Vokes EE, George CM, Szeto L et al. An ongoing study of pemetrexed plus chest radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancers. Lung Cancer (2002) (Abstract 515P).
36. Hanauske AR, Chen V, Paoletti P, Niyikiza, C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6, 363-373 (2001).
37. Alati T, Worzalla JF, Shih C et al. Augmentation of the therapeutic activity of lometrexol - (6-R)5,10-dideazatetrahydrofolate - by oral folic acid. Cancer Res. 56, 2331-2335 (1996).
38. Roberts JD, Poplin EA, Tombes MB et al. Weekly lometrexol with daily oral folic acid is appropriate for Phase II evaluation. Cancer Chemother. Pharmacol. 45, 103-110 (2000).
39. Laohavinij S, Wedge SR, Lind MJ et al. A Phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest. New Drugs 14, 325-335 (1996).
40. Worzalla JF, Shih C, Schultz RM. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY-231514. Anticancer Res. 18, 3235-3239 (1998).
41. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 1, 545-552 (2002).
42. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am. J. Med. 96, 239-246 (1994).
43. Stabler SP, Lindenbaum J, Savage DG, Allen RH. Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81, 3404-3413 (1993).
44. Bunn P, Paoletti P, Niyikiza C et al. Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY-231514, MTA) a novel antifolate/antimetabolite. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 300).
45. Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate LY-231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a Phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17, 1194 (1999).
46. Kindler HL. Systemic Therapy for Malignant Mesothelioma. American Society of Clinical Oncology, USA, 359-367 (2002).
47. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The α-folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 121, 225-233 (2001).
48. Scagliotti GV, Shin DM, Kindler HL et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 21, 1556-1561 (2003).
49. Clarke SJ, Abratt P, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (Alimta, LY-231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann. Oncol. 13, 737-741 (2002).
50. Smit EF, Mattson K, von Pawel J, Manegold C, Clarke S, Postmus PE. Alimta (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a Phase II study. Ann Oncol. 14, 455-460 (2003).
51. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev. Anticancer Ther. 3, 435-442 (2003).
52. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY-231514, pemetrexed disodium, Alimta) and cisplatin: a multicenter Phase II trial. Ann. Oncol. 11, 435-440 (2000).
53. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92, 595-600 (2001).
54. Scagliotti G, Kortsik C, Castellano D et al. Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 2513).
55. Zinner R, Obasaju FV, Fossella VA et al. Alimta plus carboplatin in patients (pts) with advanced non-small-cell lung cancer (NSCLC): a Phase II trial. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 2580).
56. Ettinger DS. Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer. Oncology (Huntingt) 14, 49-52 (2000).
57. Martin M, Spielmann M, Namer M et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann. Oncol. 14, 1246-1252 (2003).
58. Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ. A Phase II study of pemetrexed disodium (LY-231514) in patients with locally recurrent or metastatic breast cancer. Eur. J. Cancer 37, 1366-1371 (2001).
59. John W, Picus J, Blanke CD et al. Activity of multitargeted antifolate (pemetrexed disodium, LY-231514) in patients with advanced colorectal carcinoma: results from a Phase II study. Cancer 88, 1807-1813 (2000).
60. Cripps C, Burnell M, Jolivet J et al. Phase II study of first-line LY-231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann. Oncol. 10, 1175-1179 (1999).
61. Paz-Ares L, Ciruelos E, Garcia-Carbonero R, Castellano D, Lopez-Martin A, Cortes-Funes H. Pemetrexed in bladder, head and neck and cervical cancers. Semin. Oncol. 29, 69-75 (2002).
62. Miller KD, Picus J, Blanke C et al. Phase II study of the multitargeted antifolate LY-231514 (Alimta, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann. Oncol. 11, 101-103 (2000).
63. Pivot X, Raymond E, Laguerre B et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer 85, 649-655 (2001).
64. Thodtmann R, Sauter T, Weinknecht S et al. A Phase II trial of pemetrexed in patients with metastatic renal cancer. Invest. New Drugs 21, 353-358 (2003).
65. Celio L, Buzzoni R, Longarini R, Marchiano A, Bajetta E. Pemetrexed in gastric cancer: clinical experience and future perspectives. Semin. Oncol. 29, 63-68 (2002).